Patents by Inventor Matthew S. Miller

Matthew S. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7087647
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 8, 2006
    Assignee: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Patent number: 7018999
    Abstract: Novel methods for the treatment and/or prevention of pain are presented. The methods may comprise administering to a subject in need thereof an effective amount of a stress-activated protein kinase inhibitor. Preferred compounds for use in the methods include fused pyrrolocarbazole compounds.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: March 28, 2006
    Assignee: Cephalon, Inc.
    Inventors: Lisa D. Aimone, Robert L. Hudkins, Matthew S. Miller
  • Patent number: 6919367
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: July 19, 2005
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Publication number: 20040116445
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Application
    Filed: November 18, 2003
    Publication date: June 17, 2004
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Patent number: 6670358
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: December 30, 2003
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Publication number: 20030087899
    Abstract: Novel methods for the treatment and/or prevention of pain are presented. The methods may comprise administering to a subject in need thereof an effective amount of a stress-activated protein kinase inhibitor. Preferred compounds for use in the methods include fused pyrrolocarbazole compounds.
    Type: Application
    Filed: May 15, 2002
    Publication date: May 8, 2003
    Applicant: Cephalon, Inc
    Inventors: Lisa D. Aimone, Robert L. Hudkins, Matthew S. Miller
  • Publication number: 20030069313
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Application
    Filed: October 30, 2002
    Publication date: April 10, 2003
    Applicant: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Patent number: 6492396
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: December 10, 2002
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Jeffry L. Vaught, Matthew S. Miller
  • Publication number: 20020183334
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Application
    Filed: October 26, 2001
    Publication date: December 5, 2002
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
  • Patent number: 6488164
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 3, 2002
    Assignee: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Patent number: 6455588
    Abstract: Modafinil is effective in improving symptoms of eating disorders or in stimulating appetite.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: September 24, 2002
    Assignee: Cephalon, Inc.
    Inventors: Thomas E. Scammell, Matthew S. Miller
  • Publication number: 20020128322
    Abstract: Modafinil is effective in improving symptoms of eating disorders or in stimulating appetite.
    Type: Application
    Filed: May 2, 2002
    Publication date: September 12, 2002
    Inventors: Thomas E. Scammell, Matthew S. Miller
  • Publication number: 20020082301
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Application
    Filed: December 20, 2001
    Publication date: June 27, 2002
    Applicant: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Patent number: 6346548
    Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: February 12, 2002
    Assignee: Cephalon, Inc.
    Inventors: Matthew S. Miller, Thomas E. Scammell
  • Patent number: 6207656
    Abstract: The present invention is directed, inter alia, to methods of utilizing low calcemic vitamin D analogues. Particularly, the present invention is directed to using low calcemic vitamin D analogues to treat neurodegenerative diseases and disorders, to facilitate endogenous production of neurotrophic factors, to inhibit the degradation, dysfunction or loss of neural cells and/or to enhance the phenotype of neural cells or neuronal processes.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: March 27, 2001
    Assignees: Cephalon, Inc., Leo Pharmaceutical Products
    Inventors: Susan Carswell, Pawel Dobrzanski, Lise Binderup, Fredrik Björkling, Matthew S. Miller
  • Patent number: 6184217
    Abstract: Disclosed herein are therapeutic methologies utilizing a ring substituted derivative of the indolocarbazole K-252a, the derivative represented by the formula:
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: February 6, 2001
    Assignee: Cephalon, Inc.
    Inventors: Thomas M Engber, Forrest A. Haun, Michael S. Saporito, Lisa D. Aimone, Matthew S. Miller, Ernest Knight, Jr.
  • Patent number: 5631264
    Abstract: Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: May 20, 1997
    Assignee: Sanofi Winthrop, Inc.
    Inventors: Diane L. DeHaven-Hudkins, John A. Dority, Jr., William G. Earley, Virendra Kumar, John P. Mallamo, Matthew S. Miller, Chakrapani Subramanyam
  • Patent number: 5622967
    Abstract: A compound of the formula ##STR1## wherein: Z is aryl, substituted aryl, phenyl-lower-alkyl, hetero-aryl, substituted heteroaryl, heterocycloalkyl, heterocyclocalkyl-lower-alkyl, hetero-aryl-lower-alkyl wherein one or more hydrogens of aryl and heteroaryl is optionally replaced by A and B;Y is lower cycloalkyl, aryl, phenyl-lower-alkyl, hetero-aryl, heterocycloalkyl, heterocyclocalkyl-lower-alkyl, hetero-aryl-lower-alkyl wherein one or more hydrogens of aryl and heteroaryl is optionally replaced by A and B;X is CONH.sub.2, CONHOH, tetrazole, SO.sub.2 N(R).sub.2, PO(OH).sub.2, CON(R).sub.2, or CONR--CHR--CO--A or CONR--(CHR).sub.n --A;A and B is independently H, OH, OR, halo, CF.sub.3, lower alkyl, N(R).sub.2, CON(R).sub.2, SR, NHSO.sub.2 R, hydroxy-lower-alkyl, NHCOR, NRSO.sub.2 CF.sub.3, OSO.sub.2 CF.sub.3, or CN;R is H, lower-alkyl, phenyl-lower-alkyl, hydroxy-lower-alkyl, CO-lower-alkyl, or CO--(CH.sub.2).sub.n --aryl; andn is 1, 2, or 3, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: April 22, 1997
    Assignee: Sterling Winthrop, Inc.
    Inventors: Roland E. Dolle, Todd L. Graybill, Irennegbe K. Osifo, Alex L. Harris, Matthew S. Miller, Jill S. Gregory
  • Patent number: RE39575
    Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: April 17, 2007
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Jeffry L. Vaught, Matthew S. Miller
  • Patent number: H1899
    Abstract: A method for determining a concentration of IGF-I that defines a therapeutically effective dose of IGF-I, i.e., a dose that will provide a therapeutic response in the treatment of neurological disorders for which IGF-I is utilized (including peripheral neuropathy, diabetic neuropathy, post-polio syndrome, small fiber neuropathy, ALS, and MS) is described. The method comprises determining whether a particular dose of IGF-I causes a 1.5 fold or greater increase in the homeostatic concentration of plasma IGFBP-2 in a mammal that has previously received a defined dose of IGF-I. The method of the invention can also be used to determine whether or not biological tolerance has developed to a particular dose of IGF-I.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: October 3, 2000
    Assignee: Cephalon, Inc.
    Inventors: Ratan Bhat, Matthew S. Miller, Patricia C. Contreras